GENTICIN EYE/EAR

Posology Adults, the elderly and the paediatric population Eyes: 1 or 2 drops should be instilled in the affected eye up to six times a day, or more frequently if required. (Severe infections may require 1 or 2 drops every fifteen to twenty minutes initially, reducing the frequency of instillation gradually as the infection is controlled).

Ears:

The area should be cleaned and 2 - 3 drops instilled in the affected ear three to four times a day and at night, or more frequently if required. Method of administration Auricular and ocular use.

The following adverse reactions are classified by system organ class and ranked under heading of frequency using the following convention: Not known (cannot be estimated from the available data) System organ class Frequency Undesirable effects Eye disorders Not known - local sensitivity: - vision blurred - eye irritation - burning sensation - stinging sensation - itching (eye pruritus) Ear and labyrinth disorders Not known - local sensitivity - ototoxicity - vestibular disorder: - hearing loss Skin and subcutaneous tissue disorders Not known - burning sensation - stinging - itching (pruritus): - dermatitis.

Renal and urinary disorders Not known - nephropathy toxic* - acute renal failure *Gentamicin may cause nephrotoxicity when given systemically. However, it is likely that systemic absorption following topical administration does not constitute a comparable risk.

In the event of irritation, sensitisation or super-infection, treatment should be discontinued and appropriate therapy instituted. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Long-term continuous topical therapy should be avoided. Prolonged use may lead to skin sensitisation and the emergence of resistant organisms. Cross sensitivity with other aminoglycoside antibiotics may occur. In severe infections, topical use of gentamicin should be supplemented with appropriate systemic antibiotic treatment.

Gentamicin may cause irreversible partial or total deafness when given systemically or when applied topically to open wounds or damaged skin. This effect is dose-related and is enhanced by renal and/or hepatic impairment and is more likely in the elderly.

The condition of the ear drum must always be checked before this medicinal product is prescribed. The medicinal product must not be used if the integrity of the ear drum cannot be guaranteed. Irreversible toxic effects may result from direct contact of gentamicin with the middle and inner ear.

The benefits of gentamicin therapy should be considered against the risk of infection itself causing hearing loss. Contact lenses should be removed during the period of treatment of ocular infections. Serious adverse reactions including neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic gentamicin therapy.

Although these effects have not been reported following topical otic use of gentamicin, caution is advised when used concomitantly with systemic aminoglycosides. 1555A>G mutation, including cases where the patient’s aminoglycoside serum levels were within the recommended range.

Some cases were associated with a maternal history of deafness and/or mitochondrial mutation. Mitochondrial mutations are rare, and the penetrance of this observed effect is unknown. This medicine contains benzalkonium chloride and may cause skin reactions, eye irritation and discolour soft contact lenses.

Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. Contact lenses should be removed before using this medicine and put back 15 minutes afterwards. From the limited data available, there is no difference in the adverse event profile in children compared to adults.

Generally, however, eyes in children show a stronger reaction for a given stimulus than the adult eye. Irritation may have an effect on treatment adherence in children. Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface.

Should be used with caution in dry eye patients and in patients where the cornea may be compromised. Patients should be monitored in case of prolonged use.

1 Myasthenia gravis Known or suspected perforation of the ear drum.